This study is currently not recruiting participants.

CTBM100C2407: A prospective observational study in cystic fibrosis patients with chronic respiratory Pseudomonas aeruginosa infection treated with TOBI? Podhaler? (tobramycin inhalation powder) or other FDA approved inhaled antipseudomonal antibacterial drugs

Study on Patient Response to Inhaled Medications

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to capture how patients are currently treated and how they respond to certain inhaled medications, including TOBI Podhaler.

Detailed description of study

The purpose of this study is to capture how patients are currently treated and how they respond to certain inhaled medications, including TOBI Podhaler.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: cystic fibrosis
  • Age: 100 years or below
  • Gender: All

This study investigates how patients are currently treated for their conditions and how they respond to certain inhaled medications. Inhaled medications are treatments that are breathed in through the mouth to reach the lungs directly, and this study will look at different types of these treatments.

Participants will be observed to see how they respond to the inhaled medications. The study will involve different study arms where participants may receive different inhaled treatments to compare their effects.

  • Who can participate: The eligibility criteria for participation in this study are not specified. Details will be provided upon inquiry.
  • Study details: Participants will receive inhaled medications, including the TOBI Podhaler, and their responses will be monitored. Inhaled medications are treatments that are breathed in through the mouth to reach the lungs.
Updated on 19 Feb 2024. Study ID: 1506984551

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team